Biotech Values

[jq1234]

Can't believe ARYX's tecarfarin is back:

Tecarfarin has been on this stage before. It failed a clinical trial in 2009 when it couldn’t beat warfarin—an anticoagulant drug that’s been around for decades—head to head. That led its original owner, ARYx Therapeutics, into a tailspin it never recovered from, closing down for good in 2011.

ARYx’s executives, however, didn’t give up. Founder Peter Milner took the drug over to a new company, Armetheon, in 2011. And the startup has found a new way to breathe life into tecarfarin by targeting a specific group of patients that don’t respond well to warfarin.

http://www.xconomy.com/san-francisco/2015/02/09/cardio-study-gives-life-to-armetheons-blood-thinning-drug/